MX358730B - Metodos para predecir y monitorear cicatrizacion de la mucosa. - Google Patents

Metodos para predecir y monitorear cicatrizacion de la mucosa.

Info

Publication number
MX358730B
MX358730B MX2015004272A MX2015004272A MX358730B MX 358730 B MX358730 B MX 358730B MX 2015004272 A MX2015004272 A MX 2015004272A MX 2015004272 A MX2015004272 A MX 2015004272A MX 358730 B MX358730 B MX 358730B
Authority
MX
Mexico
Prior art keywords
mucosal healing
predicting
monitoring
methods
present
Prior art date
Application number
MX2015004272A
Other languages
English (en)
Other versions
MX2015004272A (es
Inventor
Singh Sharat
Hauenstein Scott
Liu Xinjun
Kirkland Richard
Drake Katherine
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2015004272A publication Critical patent/MX2015004272A/es
Publication of MX358730B publication Critical patent/MX358730B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para predecir la probabilidad de cicatrización de la mucosa en un individuo con una enfermedad tal como enfermedad inflamatoria del intestino (IBD). Además, la presente invención proporciona métodos para monitorear la progresión de la cicatrización de la mucosa en un individuo con una enfermedad tal como IBD. Información sobre el estado de cicatrización de la mucosa derivada del uso de la presente invención también puede ayudar en la organización de la terapia y/o el monitoreo de la eficacia de un fármaco inhibidor de anti-TNFa.
MX2015004272A 2012-10-05 2013-10-02 Metodos para predecir y monitorear cicatrizacion de la mucosa. MX358730B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710491P 2012-10-05 2012-10-05
US201361824959P 2013-05-17 2013-05-17
PCT/IB2013/059077 WO2014054013A1 (en) 2012-10-05 2013-10-02 Methods for predicting and monitoring mucosal healing

Publications (2)

Publication Number Publication Date
MX2015004272A MX2015004272A (es) 2015-08-14
MX358730B true MX358730B (es) 2018-09-03

Family

ID=49447587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004272A MX358730B (es) 2012-10-05 2013-10-02 Metodos para predecir y monitorear cicatrizacion de la mucosa.

Country Status (11)

Country Link
US (1) US20150355195A1 (es)
EP (3) EP3217179B9 (es)
JP (1) JP2015532425A (es)
CN (1) CN104838270A (es)
AU (2) AU2013326070A1 (es)
CA (1) CA2887035A1 (es)
ES (2) ES2771127T3 (es)
HK (1) HK1213051A1 (es)
MX (1) MX358730B (es)
SG (1) SG11201502646RA (es)
WO (1) WO2014054013A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362132B (es) 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
MX2017004816A (es) * 2014-10-20 2017-08-02 Nestec Sa Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa.
EP3212198B1 (en) 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
GB201501612D0 (en) * 2015-01-30 2015-03-18 Univ Birmingham Assay
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
CN110646620A (zh) * 2019-09-29 2020-01-03 湖北新纵科病毒疾病工程技术有限公司 一种同时检测四项炎症标志物的方法及其试剂盒
CN111477325A (zh) * 2020-04-09 2020-07-31 赣南师范大学 基于粒子群优化算法对引发肠道溃疡疾病进行鉴别的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ATE193601T1 (de) 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7531352B2 (en) * 2000-04-20 2009-05-12 The United States Of America As Represented By The Department Of Health And Human Services Inducible plasmid vector encoding TGF-β and use thereof
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7439019B2 (en) 2003-11-03 2008-10-21 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
CN101802618B (zh) 2007-07-13 2015-02-25 雀巢产品技术援助有限公司 利用基于抗体的阵列选择肺癌治疗药物
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
EP2491385B1 (en) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
AU2010324735A1 (en) * 2009-11-25 2012-07-12 Nestec S.A. Novel genomic biomarkers for irritable bowel syndrome diagnosis
CA2801575A1 (en) * 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis
EP2630495B1 (en) 2010-10-18 2017-02-08 Nestec S.A. Methods for determining anti-drug antibody isotypes
WO2012088337A1 (en) 2010-12-23 2012-06-28 Prometheus Laboratories Inc. Drug selection for malignant cancer therapy using antibody-based arrays
KR20140008397A (ko) 2011-02-17 2014-01-21 네스텍 소시에테아노님 항-ＴＮＦα 약물에 대한 자가항체 검출을 위한 검정법
ES2734673T3 (es) 2011-03-02 2019-12-11 Nestle Sa Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링

Also Published As

Publication number Publication date
EP3217179B9 (en) 2020-06-10
SG11201502646RA (en) 2015-05-28
MX2015004272A (es) 2015-08-14
WO2014054013A1 (en) 2014-04-10
EP3640645A1 (en) 2020-04-22
EP2904405B1 (en) 2017-05-31
ES2638971T3 (es) 2017-10-24
JP2015532425A (ja) 2015-11-09
EP3217179B1 (en) 2020-01-08
CA2887035A1 (en) 2014-04-10
EP3217179A1 (en) 2017-09-13
US20150355195A1 (en) 2015-12-10
HK1213051A1 (zh) 2016-06-24
CN104838270A (zh) 2015-08-12
AU2013326070A1 (en) 2015-04-23
ES2771127T3 (es) 2020-07-06
AU2019204276A1 (en) 2019-07-04
EP2904405A1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
MX358730B (es) Metodos para predecir y monitorear cicatrizacion de la mucosa.
PH12021550052A1 (en) Methods of treating and preventing graft versus host disease
EP3065777A4 (en) Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
IN2015DN01480A (es)
MX2013004338A (es) Secuencias de repeticiones palindromicas cortas separadas regularmente agrupadas-cas (crisp-cas).
BR112013027378A2 (pt) nó b evoluído, equipamento de usuário, método implementado por computador e dispositivo de equipamento de usuário
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
EA201691314A1 (ru) Терапевтические способы и композиции
UY34582A (es) Anticuerpos anti-cxcr3
WO2012166626A8 (en) Reagents and methods for treating dental disease
UY4281Q (es) Juguera
MX365403B (es) Peptidos y metodos para usarlos.
MX2021006626A (es) Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
SG11201603013XA (en) Sense-antisense gene pairs for patient stratification, prognosis, and therapeutic biomarkers identification
BR112013024363A2 (pt) método, e aparelho
GB201102108D0 (en) Diagnostic method
NZ712023A (en) Caix stratification based cancer treatment
TN2015000020A1 (en) Molecular markers and methods for early sex determination in date palms
MX358340B (es) Extractos de tomillo silvestre y su uso.
BR112012020040A2 (pt) monte carlo via cadeias de markov do tipo distribuído.
UY4243Q (es) Banco
IN2014DN07191A (es)
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
IN2014DN00168A (es)

Legal Events

Date Code Title Description
FG Grant or registration